Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JYP0322 |
| Synonyms | |
| Therapy Description |
JYP0322 selectively inhibits ROS1, with activity against ROS1 G2032R, which potentially leads to decreased proliferation of ROS1-positive tumor cells (Cancer Res (2025) 85 (8_Supplement_2): CT052, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JYP0322 | JYP-0322|JYP 0322 | ROS1 Inhibitor 23 | JYP0322 selectively inhibits ROS1, with activity against ROS1 G2032R, which potentially leads to decreased proliferation of ROS1-positive tumor cells (Cancer Res (2025) 85 (8_Supplement_2): CT052, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 fusion ROS1 G2032R | lung non-small cell carcinoma | predicted - sensitive | JYP0322 | Case Reports/Case Series | Actionable | In a Phase I trial, JYP0322 treatment demonstrated safety and activity in patients with non-small cell lung cancer harboring ROS1 fusions and ROS1 G2032R, resulting in an objective response rate of 71.4% (5/7) (Cancer Res (2025) 85 (8_Supplement_2): CT052; NCT06128148). | detail... |
| ROS1 fusion | lung non-small cell carcinoma | predicted - sensitive | JYP0322 | Phase I | Actionable | In a Phase I trial, JYP0322 treatment demonstrated safety and activity in patients with non-small cell lung cancer harboring ROS1 fusions, resulting in an objective response rate (ORR) of 85.7% (12/14) in ROS1-TKI naive patients and an ORR of 54.5% (12/22) in patients treated with at least 2 lines of systemic therapy and 1 line of a ROS1-TKI (Cancer Res (2025) 85 (8_Supplement_2): CT052; NCT06128148). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|